Thermo Fisher Scientific to acquire CorEvitas for $912.5 M

07 July 2023 | News

Advances world-class clinical research capabilities with leading regulatory-grade registries platform

Thermo Fisher Scientific Inc., an American supplier of scientific instrumentation, reagents and consumables, and software services, has entered into a definitive agreement to acquire CorEvitas, LLC, a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity, for $912.5 million in cash.

Real-world evidence is the collection and use of patient health outcomes data gathered through routine clinical care. CorEvitas, based in Waltham, Massachusetts, with operations focused in the US, provides regulatory-grade, real-world evidence solutions to pharmaceutical and biotechnology companies with objective data and clinical insights to improve patient care and clinical outcomes. CorEvitas manages 12 registries, including nine autoimmune and inflammatory syndicated registries. Its multi-therapeutic data intelligence platform builds and scales multiple clinical registries across specific therapeutic areas to gather structured patient clinical data spanning more than 400 investigator sites and over 100,000 patients followed longitudinally.

CorEvitas has been a partner to pharma and biotech customers for more than 20 years. With approximately 300 employees, operational momentum and strong leadership, CorEvitas is well positioned to grow its revenue organically in the low double digits, with expected revenue of $110 million in 2023.

Upon completion of the acquisition, CorEvitas will become part of Thermo Fisher's Laboratory Products and Biopharma Services segment.